Periodontal Therapeutics Market To Reach $1.41 Billion By 2030

Periodontal Therapeutics Market Growth & Trends

The global periodontal therapeutics market size is anticipated to reach USD 1.41 billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of periodontal diseases aided by the growing geriatric population. According to an article published by NCBI, in September 2023, the percentage of older adults affected by the disease is anticipated to rise from 42.44% in 2020 to 54.57% by 2050. Mild periodontal diseases are predicted to continue being the most common type, accounting for 80.39% of cases. Additionally, the number of untreated cavities in teeth is expected to increase by 75.2% between 2020 and 2050.

Increasing awareness about oral health fuels the growth of the market. Numerous campaigns have been created using data from formative needs assessments, focusing on the widespread issue of poor dental health in various populations. These initiatives aimed to increase awareness and knowledge about periodontal health, promote self-care dental preventive behaviors, and encourage the utilization of dental health services. Certain campaigns were tailored to specific demographics, including adults, children, parents of infants, and disadvantaged socio-economic groups considered to be at higher risk for dental problems. The Perio-Year Campaign in Norway targeted individuals aged 15 and above to increase awareness. As part of the initiative, dentists received one year of training to reinforce campaign messages during patient consultations. The campaign utilized diverse media channels and distributed informational booklets to grocery stores, pharmacies, and dental offices.

The emergence of antibiotic-resistant strains of bacteria associated with periodontal diseases necessitates several key actions and considerations. For instance, in October 2022, a research study focused on assessing antimicrobial resistance in microorganisms associated with periodontal diseases underscores the importance of ongoing research in understanding the scope of resistance among these bacteria. This investigation highlights the necessity for developing targeted treatments and strategies to address antibiotic resistance effectively.The study emphasizes the detrimental impact of healthcare professionals on antimicrobial resistance due to indiscriminate prescribing of antimicrobials. This emphasizes the significance of adhering to appropriate prescribing practices and the necessity for healthcare providers to possess awareness regarding the resistance patterns of the bacteria they are addressing.

Furthermore, technological advancements in drug development have been significantly influenced by the integration of big data mining, systems biology, and deep learning methods. These advancements aim to enhance the discovery and development of novel drugs for the treatment of the diseases, which are characterized by inflammation and infection in the gums and periodontal tissues. One key methodology involves leveraging big data mining to analyze genome-wide microarray datasets, such as the GSE10334 dataset, which contains data from individuals with moderate to severe periodontitis. This approach enables the identification of candidate genes, protein-protein interaction (PPIN) networks, and regulatory networks (GRNs) involved in the disease process. Applying system identification and system order detection methods, researchers can pinpoint genuine gene-wide gene expression networks (GWGENs) for both diseased and healthy control groups. This step is crucial for elucidating the molecular mechanisms underlying the disease and identifying potential targets for drug development.

 Request a free sample copy or view report summary: Periodontal Therapeutics Market Report

Periodontal Therapeutics Market Report Highlights

• The chronic periodontal disease segment held the largest share of the market in 2023. It can be attributed to the high treatment rate of the disease due to significant discomfort to the patients, high treatment adherence rate, and overall, a growing prevalence of the disease.

• The doxycycline drug type dominated the market in 2023. Doxycycline, even at lower concentrations, has been found to inhibit matrix metalloproteinase-8 (MMP-8), an enzyme abundant in periodontitis.

• Hospital pharmacies distribution channel held the largest share of the market in 2023. The high prescription rates at hospitals, high patient preference of purchase prescribed medications from hospital pharmacies, and increasing number of patients visiting hospitals for periodontal diseases are driving the growth of this segment.

• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of the disease, and favorable regulatory environment.

Periodontal Therapeutics Market Segmentation

Grand View Research has segmented the global periodontal therapeutics market based on disease, drug type, distribution channel, and region:

Periodontal Therapeutics Disease Category Outlook (Revenue, USD Million; 2018 - 2030)

• Gingivitis

• Chronic Periodontal Disease

• Aggressive Periodontal Disease

• Others

Periodontal Therapeutics Drug Type Outlook (Revenue, USD Million; 2018 - 2030)

• Doxycycline

• Minocycline

• Chlorhexidine

• Metronidazole

• Other drug types

Periodontal Therapeutics Distribution Channel Outlook (Revenue, USD Million; 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Channel

Periodontal Therapeutics Region Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Periodontal Therapeutics Market

• Pfizer Inc. 

• Lupin Ltd

• Teva Pharmaceuticals USA, Inc.

• Sun Pharmaceutical Industries Ltd.

• Tokyo Chemical Industry Co., Ltd.

• Bausch Health Companies Inc.

• USAntibiotics

• Melinta Therapeutics LLC

• Cipla, Inc.

• Chartwell Pharmaceuticals LLC.